Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03287687 · ClinicalTrials.gov registry record · Phase 4

Safety and Efficacy of CO2 for Endoscopy

A Phase 4 study, sponsored by Warren Bishop.

Completed
Registry status
Phase 4
Development phase
180
Enrollment target

NCT03287687: Completed Phase 4 study, sponsored by Warren Bishop.

NCT03287687 is a Phase 4 study that has completed, run by Warren Bishop. The registered enrollment target is 180 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (65% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03287687, a Phase 4 study, has completed, sponsored by Warren Bishop.

COMPLETED
Registry status
Phase 4
Development phase
180 participants
Enrollment target

Study Summary

Hypothesis: Carbon dioxide gas use for endoscopic insufflation is safe and results in less abdominal distension and discomfort; it is equally effective as air in pediatric patients undergoing endoscopic procedures. Aim 1: Determine the occurrence and severity of abdominal discomfort and distension associated with endoscopic procedures at baseline, upon awakening from anesthesia, at discharge and at 4 hours after discharge in carbon dioxide group when compared to the air group. Aim 2: Determine if the expertise level of the endoscopist contributes to abdominal discomfort and distension following endoscopy, and whether this differs in the carbon dioxide group versus air group. Aim 3: Determine if carbon dioxide is as effective as air for insufflation.

Primary Outcome

Change in abdominal girth from baseline to end of procedure (Time Difference 1) or Change in abdominal girth from baseline to time of discharge ((Time Difference 2)

Interventions

  • DRUG Carbon dioxide (CO2) gas insufflation
  • DRUG Air insufflation

Trial Details

FieldValue
Enrollment Target 180 participants
Start Date 2017-11-27
Est. Completion 2019-04-09
Phase Phase 4
Warren Bishop

3 total trials

What the finished NCT03287687 record still lists

NCT03287687 is an interventional study that assigns participants to a tested intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (65% lower).

The record links to 0 conditions, and to 2 interventions - of which Carbon dioxide (CO2) gas insufflation is the first listed.

NCT03287687 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03287687 about?

NCT03287687 is a clinical study titled "Safety and Efficacy of CO2 for Endoscopy". Hypothesis: Carbon dioxide gas use for endoscopic insufflation is safe and results in less abdominal distension and discomfort; it is equally effective as air in pediatric patients undergoing endoscopic procedures. Aim 1: Determine the occurrence and severity of abdominal discomfort and distensio...

What is the current status of trial NCT03287687?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 180 participants. The study started on 2017-11-27. Estimated completion is 2019-04-09.

What interventions are being tested in trial NCT03287687?

The interventions under investigation include: Carbon dioxide (CO2) gas insufflation (DRUG), Air insufflation (DRUG).

Who is sponsoring clinical trial NCT03287687?

This trial is sponsored by Warren Bishop, which has 3 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03287687's enrollment target sits among peer trials

180 466th of 2000 higher than 1,525 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01558804 · 180 participants

    GRoup A StrePtococcus

  • NCT02932176 · 180 participants

    Machine Learning for Handheld Vascular Studies

  • NCT03384563 · 180 participants · Phase 4

    Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane

  • NCT03423628 · 180 participants · Phase 1

    A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03287687, the US trial registry maintained by the National Library of Medicine. NCT03287687 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.